Frequent Recurrence in Pancreatic Adenocarcinoma Arising from IPMN, with Treatment Improving Survival

An international multicenter study analyzed 459 patients who underwent pancreatic resection for adenocarcinoma originating from intraductal papillary mucinous neoplasia (IPMN). Results showed that recurrence was common, with 45.5% experiencing it, including 23.2% with early recurrence within a year. Treatment of recurrence, such as adjuvant chemotherapy and other modalities, significantly improved overall survival, with a median survival of 27.0 months, compared to 14.6 months without treatment. The study highlights the need for vigilance in monitoring IPMN-related adenocarcinoma and considering treatment upon recurrence.